Can the Dose of Belimumab be Reduced in Patients with Systemic Lupus Erythematosus?
Rua-Figueroa I, Altabás-González I, Mouriño C, Roberts K, Hernández-Martín A, Casafont-Solé I, Font-Urgelles J, Román-Ivorra JA, Navarro MR, Galindo-Izquierdo M, Salman-Monte TC, Narváez J, Vidal-Montal P, García-Villanueva MJ, Garrote-Corral S, Blazquez-Canamero MA, Fernandez-Cid CM, Piqueras-García M, Martínez-Barrio J, Sánchez-Lucas M, Cortés-Hernández J, Penzo E, Calvo J, de Dios JR, Alvarez-Rodríguez B, Vasques-Rocha M, Tomero E, Menor-Almagro R, Gandía M, Gómez-Puerta JA, Frade-Sosa B, Ramos-Giráldez C, Trapero-Pérez C, Diez E, Moriano C, Muñoz-Jiménez A, Pego-Reigosa JM.
Rua-Figueroa I, et al. Among authors: roman ivorra ja.
Rheumatology (Oxford). 2024 May 13:keae270. doi: 10.1093/rheumatology/keae270. Online ahead of print.
Rheumatology (Oxford). 2024.
PMID: 38741198